These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 4589131)

  • 21. Two different types of ADP-ribosyltransferase C3 from Clostridium botulinum type D lysogenized organisms.
    Moriishi K; Syuto B; Saito M; Oguma K; Fujii N; Abe N; Naiki M
    Infect Immun; 1993 Dec; 61(12):5309-14. PubMed ID: 8225604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isolation of nontoxigenic variants associated with enhanced sporulation and alteration in the cell wall from Clostridium botulinum type a 190L by treatment with detergents.
    Takumi K; Kinouchi T; Kawata T
    Microbiol Immunol; 1980; 24(6):469-77. PubMed ID: 6997693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adsorption of Clostridium botulinum cultures of phage controlling type C botulinum toxin production.
    Oguma K; Iida H; Sugiyama H
    Jpn J Med Sci Biol; 1979 Apr; 32(2):125-6. PubMed ID: 396393
    [No Abstract]   [Full Text] [Related]  

  • 24. Use of ganglioside affinity filters to identify toxigenic strains of Clostridium botulinum types C and D.
    Hayes S
    Infect Immun; 1979 Oct; 26(1):150-6. PubMed ID: 387601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adsorption to Clostridium botulinum cultures of phage controlling type C botulinum toxin production.
    Oguma K; Sugiyama H
    Proc Soc Exp Biol Med; 1978 Oct; 159(1):61-4. PubMed ID: 362423
    [No Abstract]   [Full Text] [Related]  

  • 26. Serological studies of Clostridium botulinum type E and related organisms. II. Serology of spores.
    Solomon HM; Lynt RK; Kautter DA; Lilly T
    J Bacteriol; 1969 May; 98(2):407-14. PubMed ID: 4891254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Production of C2 toxin by Clostridium botulinum types C and D as determined by its vascular permeability activity.
    Ohishi I; Sakaguchi G
    Infect Immun; 1982 Jan; 35(1):1-4. PubMed ID: 7033132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phage-conversion of toxigenicity in Clostridium botulinum types C and D.
    Iida H; Oguma K; Inoue K
    Jpn J Med Sci Biol; 1974 Apr; 27(2):101-3. PubMed ID: 4601039
    [No Abstract]   [Full Text] [Related]  

  • 29. Antigenic relationships among the proteolytic and nonproteolytic strains of Clostridium botulinum.
    Solomon HM; Lynt RK; Kautter DA; Lilly T
    Appl Microbiol; 1971 Feb; 21(2):295-9. PubMed ID: 4927406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence for plasmid-mediated toxin and bacteriocin production in Clostridium botulinum type G.
    Eklund MW; Poysky FT; Mseitif LM; Strom MS
    Appl Environ Microbiol; 1988 Jun; 54(6):1405-8. PubMed ID: 2843093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antigenic similarity of toxins produced by Clostridium botulinum type C and D strains.
    Oguma K; Syuto B; Iida H; Kubo S
    Infect Immun; 1980 Dec; 30(3):656-60. PubMed ID: 6785231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemical classification of Clostridium botulinum type C and D strains and their nontoxigenic derivatives.
    Oguma K; Yamaguchi T; Sudou K; Yokosawa N; Fujikawa Y
    Appl Environ Microbiol; 1986 Feb; 51(2):256-60. PubMed ID: 3513703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of a monoclonal antibody-based immunoassay for detecting type A Clostridium botulinum toxin produced in pure culture and an inoculated model cured meat system.
    Gibson AM; Modi NK; Roberts TA; Shone CC; Hambleton P; Melling J
    J Appl Bacteriol; 1987 Sep; 63(3):217-26. PubMed ID: 3323154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relation between toxicity and toxin-related-antigen contents of Clostridium botulinum types C and D cultures as determined by mouse bioassay and ELISA.
    Notermans S; Dufrenne J; Kozaki S
    Jpn J Med Sci Biol; 1982; 35(5-6):203-11. PubMed ID: 6761472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterogeneities of two components of C2 toxin produced by Clostridium botulinum types C and D.
    Ohishi I; Okada Y
    J Gen Microbiol; 1986 Jan; 132(1):125-31. PubMed ID: 3086490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Phage conversion of toxigenicity in Clostridium botulinum].
    Khotenko SG; Perova EV; Golikov VI; Bulatova TI; Il'iashenko BN
    Zh Mikrobiol Epidemiol Immunobiol; 1980 Aug; (8):25-8. PubMed ID: 7004020
    [No Abstract]   [Full Text] [Related]  

  • 37. [Toxin production and phage in Clostridium botulinum].
    Iida H
    Nihon Saikingaku Zasshi; 1985 Sep; 40(5):827-34. PubMed ID: 3908743
    [No Abstract]   [Full Text] [Related]  

  • 38. Dual toxin-producing strain of Clostridium botulinum type Bf isolated from a California patient with infant botulism.
    Barash JR; Arnon SS
    J Clin Microbiol; 2004 Apr; 42(4):1713-5. PubMed ID: 15071029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phage-conversion of toxigenicity in Clostridium botulinum types C and D.
    Inoue K; Iida H
    Jpn J Med Sci Biol; 1971 Feb; 24(1):53-6. PubMed ID: 4931809
    [No Abstract]   [Full Text] [Related]  

  • 40. Aerobic growth and toxigenicity of Clostridium botulinum types A and B.
    Dezfulian M
    Folia Microbiol (Praha); 1999; 44(2):167-70. PubMed ID: 10588051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.